Dark

BMRN
BioMarin Pharmaceuticals Inc
stock NASDAQ

Market Open

Jul 10, 2025 3:48:05 PM EDT

58.78USD-1.483%(-0.89)1,051,807

56.00Bid 58.80Ask 2.80Spread

Pre-market

Jul 10, 2025 9:19:30 AM EDT

60.04USD+0.620%(+0.37)1,139

After-hours

Jul 9, 2025 4:00:30 PM EDT

59.67USD+0.008%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 28, 2022

09:50PM EST Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN PR Newswire

Jan 14, 2022

11:17PM EST Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN PR Newswire

Jan 10, 2022

03:50PM EST Biomarin Pharmaceutical shares were trading higher after the company said its hemophilia gene therapy met its efficacy endpoints. Benzinga

06:29AM EST BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis Benzinga

Jan 9, 2022

09:44PM EST BioMarin Pharmaceutical Inc. (BMRN) announced stable and durable annualized bleed control in phase 3 GENEr8-1 study of valoctocogene roxaparvovec in adults with Severe Hemophilia A. The 134-participant study met all primary and secondary efficacy endpoints at two year analysis. RTTNews

03:14PM EST Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis PR Newswire

Jan 4, 2022

06:01AM EST BioMarin to Participate in Two Virtual Investor Conferences in January PR Newswire

Dec 20, 2021

11:51AM EST BioMarin Granted FDA Orphan Designation For Treatment Of Hereditary Angioedema Benzinga

Dec 19, 2021

09:36PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Dec 16, 2021

04:06PM EST BioMarin Pharma Reports Multi-Year Strategic Collab For Discovery, Development, Commercialization Of Adeno-Associated Virus Gene Therapies To Treat Genetic Cardivascular Disesases Benzinga

04:06PM EST BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop PR Newswire

Dec 15, 2021

04:07PM EST BioMarin Appoints Mark Alles To Board Of Directors RTTNews

04:06PM EST BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of PR Newswire

Dec 7, 2021

05:14PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Nov 30, 2021

08:45AM EST BioMarin to Hold Virtual R&D Day at 11:00am ET Today PR Newswire

Nov 29, 2021

08:31AM EST BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire

Nov 24, 2021

03:34PM EST Levi & Korsinsky, LLP, Researching Possible Securities Law Violations - PR Newswire

Nov 22, 2021

11:10AM EST Where Biomarin Pharmaceutical Stands With Analysts Benzinga

10:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021 Benzinga

09:30AM EST Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $105 Benzinga

08:25AM EST Morgan Stanley Maintains Equal-Weight on Biomarin Pharmaceutical, Raises Price Target to $90 Benzinga

07:30AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:16AM EST William Blair Upgrades Biomarin Pharmaceutical to Outperform Benzinga

04:42AM EST SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $115 Benzinga

Nov 19, 2021

05:25PM EST BioMarin Pharmaceutical Inc. (BMRN) Friday said that the U.S. Food and Drug Administration has granted accelerated approval to Voxzogo, the first drug approved by the FDA to improve growth in children with most common form of dwarfism. RTTNews

01:49PM EST BioMarin Says Average Net Price Per Patient Per Year Is Estimated At $240,000 For Voxzogo, Says US Wholesale Acquisition Cost, Or List Price, Per Vial Is $899 For Voxzogo Benzinga

10:44AM EST BioMarin Receives FDA Approval For VOXZOGO RTTNews

10:43AM EST Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates PR Newswire

10:39AM EST FDA Approves BioMarin's Vosoritide For Children With Most Common Form Of Dwarfism Benzinga

Nov 15, 2021

11:09AM EST Entos, BioMarin Report Deal For Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform Benzinga

10:45AM EST SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $112 Benzinga

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

08:32AM EST Entos And BioMarin Enter Agreement To See Entos Apply Its Fusogenix Nucleic Acid Delivery Technology RTTNews

08:30AM EST Entos and BioMarin Enter into Agreement for Product Candidates Incorporating PR Newswire

Nov 9, 2021

03:23PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Oct 28, 2021

05:50PM EDT 17:50 Thursday, October 28, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $152 Price Target RTTNews

09:16AM EDT Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $100 Benzinga

07:14AM EDT BioMarin's Q3 Net Income Hit By Lower Product Sales Benzinga

Oct 27, 2021

06:14PM EDT Biomarin Pharmaceutical: Q3 Earnings Insights Benzinga

05:04PM EDT BioMarin Lifts FY Guidance Driven By Product Demand RTTNews

04:49PM EDT BioMarin Sees FY21 Sales $1.82B-$1.88B vs $1.85B Est. Benzinga

04:48PM EDT Biomarin Pharmaceutical Q3 EPS $(0.20) Beats $(0.25) Estimate, Sales $408.70M Miss $435.32M Estimate Benzinga

04:15PM EDT BioMarin Q3 Loss/share $0.29 Vs. Profit $4.01 Year Ago RTTNews

04:06PM EDT BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates PR Newswire

03:43AM EDT Earnings Scheduled For October 27, 2021 Benzinga

Oct 25, 2021

08:34PM EDT /C O R R E C T I O N -- Pomerantz LLP/ PR Newswire

03:49PM EDT Gainey McKenna & Egleston Announces A ClassAction GlobeNewswire Inc

08:31AM EDT BioMarin to Participate in Four Upcoming Virtual Investor Conferences PR Newswire

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 23, 2021

12:00AM EDT Pomerantz Law Firm Announces the Filing of a Class Action Against BioMarin PR Newswire

Oct 16, 2021

04:15PM EDT Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More Benzinga

Oct 12, 2021

08:31AM EDT BioMarin to Host Third Quarter 2021 Financial Results Conference Call and PR Newswire

Oct 4, 2021

08:33AM EDT BioMarin Names Harold Bernstein SVP, Chief Medical Officer And Head Of Clinical Development RTTNews

08:31AM EDT BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical PR Newswire

Sep 9, 2021

11:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 Benzinga

06:51AM EDT Stifel Upgrades Biomarin Pharmaceutical to Buy, Raises Price Target to $96 Benzinga

Sep 7, 2021

09:54AM EDT Price To Earnings Ratio Insights For Biomarin Pharmaceutical Benzinga

08:51AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Sept. 7, 2021: PLAY, SPOT, MTCH, BMRN, RNXT Benzinga

06:11AM EDT FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder Benzinga

Sep 6, 2021

02:27AM EDT Based on interim safety findings from a pre-clinical, non-GLP pharmacology study, FDA has placed a clinical hold on the BMN 307 Phearless Phase 1/2 study, BioMarin Pharmaceutical Inc. (BMRN) said. The study is evaluating BMN 307, an investigational AAV5-phenylalanine hydroxylase gene therapy in adults with phenylketonuria. RTTNews

02:06AM EDT BioMarin : FDA Places Clinical Hold On BMN 307 Phearless Phase 1/2 Gene Therapy Study In Adults With Phenylketonuria RTTNews

02:01AM EDT U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy PR Newswire

Aug 30, 2021

07:40AM EDT 07:40 Monday, August 30, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $152 Up From $141 Price Target RTTNews

Aug 27, 2021

11:50AM EDT Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval Benzinga

09:17AM EDT BioMarin Pharmaceutical Inc. (BMRN) said the European Commission has granted marketing authorization for VOXZOGO (vosoritide). It is the first medicine to be approved to treat children with achondroplasia in Europe. Achondroplasia is the most common cause of dwarfism. RTTNews

09:04AM EDT EU Oks BioMarin's VOXZOGO For Treatment Of Children With Achondroplasia From Age 2 Until Growth Plates Close RTTNews

09:02AM EDT European Commission Approves BioMarin's VOXZOGO (vosoritide) For Treatment Of Children With Achondroplasia From Age 2 Until Growth Plates Close Benzinga

09:01AM EDT Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close PR Newswire

Aug 25, 2021

08:31AM EDT BioMarin to Participate in Three Upcoming Virtual Investor Conferences PR Newswire

Jul 29, 2021

10:52AM EDT RBC Capital Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $88 Benzinga

07:13AM EDT BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance Benzinga

Jul 28, 2021

04:51PM EDT Biomarin Pharmaceutical: Q2 Earnings Insights Benzinga

04:17PM EDT BioMarin Raises FY21 Total Revenue Guidance From $1.75B-$1.85B To $1.79B-$1.88B vs $1.82B Est. Benzinga

04:10PM EDT BioMarin Q2 EPS $0.07 Vs. Loss $0.16 Year Ago RTTNews

04:05PM EDT Biomarin Pharmaceutical Q2 EPS $0.07 Beats $(0.11) Estimate, Sales $501.70M Beat $448.79M Estimate Benzinga

04:03PM EDT BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates PR Newswire

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

04:27AM EDT Earnings Scheduled For July 28, 2021 Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 22, 2021

09:27AM EDT UPDATE: Lixte Says 'vosoritide (BioMarin), was even more effective than vosorotide alone in stimulating bone length and cartilage area in a mouse model of the most common form of dwarfism' Benzinga

08:30AM EDT 08:29 Thursday, July 22, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $141 Price Target RTTNews

Jul 21, 2021

12:03PM EDT BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy Benzinga

10:21AM EDT BioMarin Pharmaceutical Inc.'s (BMRN) long-term clinical data from the ongoing phase 1/2 study of valoctocogene roxaparvovec in adults with Severe Hemophilia A demonstrated continued, durable clinical benefit. RTTNews

10:04AM EDT BioMarin Announces Data For Valoctocogene Roxaparvovec, Gene Therapy Treatment For Adults With Severe Hemophilia A RTTNews

10:03AM EDT Biomarin Pharmaceutical Announces Oral Presentation At International Society On Thrombosis And Haemostasis 2021 Virtual Congress Benzinga

10:01AM EDT Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstrating Continued, Durable Clinical Benefit PR Newswire

Jul 19, 2021

01:37PM EDT BioMarin Pharmaceutical Inc. (BMRN) Monday announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in its positive pivotal study, GENEr8-1, during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress. RTTNews

01:16PM EDT BioMarin Unveils News Data From Late-Stage Hemophilia A Gene Therapy Candidate Benzinga

11:07AM EDT BioMarin Phase 3 Trial On Valoctocogene Roxaparvovec Shows Superiority To Factor VIII Prophylaxis In Efficacy Endpoints RTTNews

11:01AM EDT BioMarin Announces Oral Presentation Of 1-Year Results From Phase 3 Pivotal Trial With Valoctocogene Roxaparvovec Gene Therapy In Adults With Sever Hemophilia A At International Society On Thrombosis A nd Haemostasis 2021 Virtual Congress Benzinga

11:01AM EDT Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress PR Newswire

Jul 16, 2021

07:06AM EDT 07:05 Friday, July 16, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $141 Price Target RTTNews

Jul 15, 2021

09:39AM EDT BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22 Benzinga

09:00AM EDT The European Medicines Agency or EMA validated BioMarin Pharmaceutical Inc.'s (BMRN) Marketing Authorization Application or MAA for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A, the company said in a statement. RTTNews

08:37AM EDT Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A PR Newswire

08:36AM EDT AMMO Announces The European Medicines Agency Has Validated Co.'s Marketing Authorization Application For Valoctocogene Roxaparvovec Benzinga

08:35AM EDT EMA Validates BioMarin's MAA For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A RTTNews

Jul 14, 2021

08:32AM EDT BioMarin to Host Second Quarter 2021 Financial Results Conference Call and PR Newswire

Jul 2, 2021

09:07AM EDT BioMarin Announces 12 Presentations At International Society On Thrombosis And Haemostasis (ISTH) 2021 Virtual Congress Benzinga

09:07AM EDT BioMarin Announces 12 Presentations On Thrombosis And Haemostasis RTTNews

09:05AM EDT BioMarin Announces 12 Presentations at the International Society on Thrombosis PR Newswire

Jun 29, 2021

08:25AM EDT 08:25 Tuesday, June 29, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $141 Price Target RTTNews

Jun 28, 2021

08:48AM EDT Biotechnology company BioMarin Pharmaceutical Inc. (BMRN) announced Tuesday that it has resubmitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. RTTNews

08:45AM EDT BioMarin Resubmits Marketing Authorization Application To European Medicines Agency For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A Benzinga

08:33AM EDT BioMarin Resubmits MAA To EU For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A RTTNews

08:31AM EDT Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A PR Newswire

Jun 25, 2021

01:30PM EDT EMA's Advisory Committee Backs Approval Of BioMarin's Dwarfism Candidate Benzinga

07:57AM EDT BioMarin Gets Positive CHMP Opinion For Vosoritide To RTTNews

07:32AM EDT BioMarin Gets Positive CHMP Opinion In Europe For Vosoritide For Children With Achondroplasia RTTNews

07:30AM EDT BioMarin Receives Positive CHMP Opinion In Europe For Vosoritide For Treatment Of Children With Achondroplasia From Age 2 Until Growth Plates Close Benzinga

07:29AM EDT Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close PR Newswire

Jun 15, 2021

08:31AM EDT BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma PR Newswire

May 27, 2021

08:31AM EDT BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire

May 24, 2021

12:11PM EDT EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy Benzinga

08:49AM EDT The European Medicines Agency or EMA has granted its request for accelerated assessment of valoctocogene roxaparvovec, for adults with severe hemophilia A, BioMarin Pharmaceutical Inc. (BMRN) said in a statement. RTTNews

08:38AM EDT European Medicines Agency Grants BioMarin's Request For Accelerated Assessment Of Valoctocogene Roxaparvovec For Treatment Of Severe Hemophilia A Benzinga

08:35AM EDT BioMarin: EMA Grants Request For Accelerated Assessment Of Valoctocogene Roxaparvovec For Severe Hemophilia A RTTNews

08:31AM EDT European Medicines Agency Grants BioMarin's Request for Accelerated Assessment PR Newswire

May 19, 2021

01:05PM EDT Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit Benzinga

10:27AM EDT BioMarin Pharmaceutical Inc. (BMRN), in an update on phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, said Wednesday that the safety profile of valoctocogene roxaparvovec in the study remains consistent with previously reported data with no delayed-onset treatment related adverse events. RTTNews

08:40AM EDT BioMarin Pharma Offers Update To Results From Open-Label Phase 1/2 Study Of Valoctocogene Roxaparvovec For Adults With Severe Hemophilia A Benzinga

08:36AM EDT BioMarin Updates On Results From Open-label Phase 1/2 Study Of Valoctocogene Roxaparvovec RTTNews

08:31AM EDT Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A PR Newswire

May 18, 2021

08:31AM EDT BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire

May 12, 2021

08:32AM EDT BioMarin Announces 6 Presentations At American Society Of Gene And Cell Therapy Virtual 2021 Annual Meeting Benzinga

08:31AM EDT BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy PR Newswire

May 3, 2021

08:31AM EDT BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire

Apr 30, 2021

05:34PM EDT 17:33 Friday, April 30, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $139 Price Target RTTNews

Apr 29, 2021

05:27PM EDT Biomarin Pharmaceutical: Q1 Earnings Insights Benzinga

05:27PM EDT Biomarin Pharmaceutical Sees FY 2021 Revs $1.75B-$1.85B Vs $1.81B Est Benzinga

04:32PM EDT Biomarin Pharmaceutical Inc. (BMRN) revealed earnings for first quarter that declined from the same period last year. RTTNews

04:21PM EDT Biomarin Pharmaceutical Q1 GAAP EPS $0.09 Beats $(0.10) Estimate, Sales $486.00M Beat $446.45M Estimate; Reaffirms FY21 Guidance' Benzinga

04:05PM EDT BioMarin Q1 EPS $0.09 Vs. $0.44 Year Ago RTTNews

04:03PM EDT BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates PR Newswire

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 28, 2021

11:07AM EDT Preview: Biomarin Pharmaceutical's Earnings Benzinga

09:12AM EDT The Allen Institute and BioMarin Pharmaceutical Inc. (BMRN) announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic diseases of the central nervous system. They did not disclose financial terms. RTTNews

08:45AM EDT Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases Benzinga

08:38AM EDT Allen Institute, BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases RTTNews

08:32AM EDT Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain PR Newswire

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 19, 2021

10:09AM EDT Morgan Stanley Maintains Equal-Weight on Biomarin Pharmaceutical, Lowers Price Target to $82 Benzinga

Apr 15, 2021

08:44AM EDT BioMarin Highlights Presentation Of Data At 2021 American College Of Medical Genetics And Genomics Annual Clinical Genetics Meeting Benzinga

08:35AM EDT BioMarin Announces New Data Demonstrating Commitment To Understanding Achondroplasia And Potential Treatment Choice RTTNews

08:31AM EDT Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice PR Newswire

Apr 13, 2021

08:31AM EDT BioMarin to Host First Quarter 2021 Financial Results Conference Call and PR Newswire

Mar 23, 2021

07:15AM EDT 07:15 Tuesday, March 23, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $139 Price Target RTTNews

Mar 22, 2021

07:40AM EDT 07:40 Monday, March 22, 2021Wedbush (RTTNews) - Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $139 Price Target RTTNews

Mar 20, 2021

11:32AM EDT BioMarin Presents Data From Open-label Long-term Extension Of Phase 3 Study Of 15 g/kg Dose Of Vosoritide At ENDO21 RTTNews

11:15AM EDT Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide PR Newswire

Mar 19, 2021

10:50PM EDT BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN Business Wire

Mar 8, 2021

12:05PM EST BioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US Benzinga

08:47AM EST Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A PR Newswire

08:47AM EST BioMarin Says FDA Granted Regenerative Medicine Advanced Therapy Designation To Valoctocogene Roxaparvovec RTTNews

08:34AM EST BioMarin Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A Benzinga

Mar 3, 2021

08:35AM EST BioMarin Completes Enrollment In Phase2 Study Of Vosoritide For Treatment Of Infants, Young Children With Achondroplasia RTTNews

08:33AM EST BioMarin Reports Completion Of Full Enrollment In Phase 2 Study Of Vosoritide For Treatment Of Infants, Young Children With Achondroplasia Benzinga

08:31AM EST BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment PR Newswire

Mar 1, 2021

12:19PM EST Canaccord Genuity Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $91 Benzinga

10:45AM EST Evercore ISI Group Upgrades Biomarin Pharmaceutical to Outperform, Raises Price Target to $100 Benzinga

Feb 26, 2021

10:50PM EST Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN PR Newswire

Feb 25, 2021

04:25PM EST BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results PR Newswire

04:25PM EST Biomarin Pharmaceutical Inc. (BMRN) announced a profit for its fourth quarter that rose from the same period last year. RTTNews

04:25PM EST Biomarin Pharmaceutical Q4 EPS $0.12 Beats $(0.19) Estimate, Sales $452.10M Beat $440.23M Estimate Benzinga

04:25PM EST BioMarin Sees FY 2021 Non-GAAP Income $170M-$220M Benzinga

04:25PM EST BioMarin Sees FY 2021 Revs $1.75B-$1.85B Vs $1.91B Est Benzinga

04:25PM EST BioMarin Q4 EPS $0.12 Vs. $0.08 Year Ago RTTNews

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 24, 2021

10:09AM EST Biomarin Pharmaceutical's Earnings Outlook Benzinga

08:31AM EST BioMarin to Participate in Four Upcoming Virtual Investor Conferences PR Newswire

Feb 18, 2021

04:02PM EST BioMarin Appoints Maykin Ho To Board Of Directors RTTNews

04:01PM EST BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, PR Newswire

Jan 28, 2021

09:03AM EST BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality PR Newswire

Jan 26, 2021

08:31AM EST BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference PR Newswire

Jan 15, 2021

10:51PM EST BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN Business Wire

Jan 11, 2021

09:55AM EST Shares of BioMarin Pharmaceutical Inc. (BMRN) are falling more than 8 percent or $7.67 in Monday's morning trade at $82.19. RTTNews

Jan 10, 2021

10:06PM EST BioMarin Pharmaceutical Inc. (BMRN) announced positive phase 3 gene therapy trial results in adults with Severe Hemophilia A. The study met all primary and secondary efficacy endpoints in one-year data set. RTTNews

07:49PM EST BioMarin Announces Positive Phase 3 Gene Therapy Trial Results In Adults With Severe Hemophilia A RTTNews

06:45PM EST Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set PR Newswire

Jan 5, 2021

08:31AM EST BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire

Dec 21, 2020

09:19AM EST BioMarin Pharmaceutical Inc. (BMRN) said that children in the open-label long-term extension of the phase 3 study of vosoritide maintained an increase in annual growth velocity through the second year of continuous treatment. It is an investigational, once daily injection analog of C-type Natriuretic Peptide. RTTNews

08:33AM EST BioMarin :Children Treated With Vosoritide Show Cumulative Height Gain Of 3.52 Cm At Year 2 Vs. Untreated Children RTTNews

08:30AM EST BioMarin Announces Benefit Maintained For Over Two Years In Children with Achondroplasia Treated With Vosoritide In Phase 3 Extension Study Benzinga

08:29AM EST BioMarin Announces Benefit Maintained for Over Two Years in Children with PR Newswire

Dec 14, 2020

08:54AM EST BioMarin Pharmaceuticals, Citrix Systems, Expedia Group, Liberty Global, Take-Two Interactive Software, Ulta Beauty Shares Quiet; Cos Removed From Nasdaq-100 Index On Friday Benzinga

Dec 12, 2020

04:43PM EST Nasdaq-100's Annual Reconstitution: Expedia and Citrix Out, Peloton and Marvell Technology In Benzinga

Dec 1, 2020

08:31AM EST BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire

Nov 24, 2020

10:00AM EST BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds GlobeNewswire Inc

Nov 23, 2020

10:51PM EST Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN PR Newswire

12:00PM EST BMRN FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, GlobeNewswire Inc

12:00PM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

11:00AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Nov 22, 2020

10:50PM EST BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN Business Wire

Nov 20, 2020

10:50PM EST BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN Business Wire

08:00AM EST Investors with losses are encouraged to contact the firm before November 24, 2020; click here to submit trade information GlobeNewswire Inc

Nov 19, 2020

12:30PM EST Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingNovember 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioMarin Pharmaceuticals, Inc. (BioMarin or the Company) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020, inclusive (the Class Period). GlobeNewswire Inc

11:08AM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws. GlobeNewswire Inc

11:00AM EST BMRN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020 Business Wire

Nov 18, 2020

11:18PM EST of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BMRN PR Newswire

10:50PM EST Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

11:00AM EST GLNG & BMRN Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds GlobeNewswire Inc

Nov 17, 2020

11:45AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

08:30AM EST BioMarin Pharmaceutical And Deep Genomics Enter Preclinical Collaboration RTTNews

08:30AM EST BioMarin And Deep Genomics To Collaborate On Advancing Programs Identified Using Artificial Intelligence; Collaboration Will Use Genomics' AI Workbench To 'identify oligonucleotide drug candidates in four rare disease indications with high unmet need' Benzinga

08:29AM EST BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified PR Newswire

Nov 16, 2020

11:08AM EST IMMINENT SHAREHOLDER DEADLINE: BioMarin Pharmaceutical, Inc. Sued GlobeNewswire Inc

11:00AM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Nov 13, 2020

09:57AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020. If you wish to serve as lead plaintiff, you must move the Court before the NOVEMBER 24, 2020 DEADLINE. GlobeNewswire Inc

Nov 12, 2020

03:56PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws. GlobeNewswire Inc

08:31AM EST BioMarin to Participate in Three Upcoming Virtual Investor Conferences PR Newswire

Nov 11, 2020

10:50PM EST ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

03:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Nov 9, 2020

08:34AM EST BioMarin Expands Vosoritide Clinical Program; Enrolls First Child In Phase 2 Study For Children With Achondroplasia RTTNews

08:31AM EST BioMarin Expands Vosoritide Clinical Program PR Newswire

Nov 8, 2020

01:53AM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Nov 7, 2020

01:50PM EST ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds BioMarin GlobeNewswire Inc

Nov 6, 2020

10:50PM EST ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

11:30AM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

09:52AM EST Biomarin Pharmaceuticals shares are trading lower after the company reported Q3 earnings results. Benzinga

08:48AM EST SVB Leerink Reiterates Outperform on Biomarin Pharmaceutical, Lowers Price Target to $108 Benzinga

Nov 5, 2020

05:15PM EST Biomarin Sees FY20 Sales $1.85B-$1.95B vs $1.86B Est. Benzinga

05:14PM EST Biomarin Pharmaceutical Q3 EPS $4.01 May Not Compare To $1.29 Estimate, Sales $476.80M Beat $454.64M Estimate Benzinga

04:14PM EST Biomarin Pharmaceutical Inc. (BMRN) released a profit for its third quarter that increased from last year. RTTNews

04:08PM EST BioMarin Q3 EPS $4.01 Vs. $0.30 Year Ago RTTNews

04:06PM EST BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million PR Newswire

03:57PM EST Notable Earnings Watchlist For Thursday, Nov. 5, 2020 After Market Close: NLOK, TTWO, Z, SYNA, GPRO, DBX, NWS, PTON, MCHP, MNST, UBER, YELP, WLL, WYNN, SQ, ROKU, BKNG, BMRN, CHMA, CHUY, AIG, GRPN, FLS, FLT, IAC, EA, ENDP Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 4, 2020

04:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

02:46PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws. GlobeNewswire Inc

08:31AM EST BioMarin to Participate in the Credit Suisse 29th Annual Virtual Healthcare PR Newswire

Nov 3, 2020

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

Nov 2, 2020

09:10PM EST FDA Accepts BioMarin's NDA For Vosoritide To Treat Children With Achondroplasia; PDUFA Action Date Aug. 20, 2021 RTTNews

08:56PM EST Food and Drug Administration Accepts BioMarin's New Drug Application for PR Newswire

02:17PM EST Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided. GlobeNewswire Inc

Oct 30, 2020

10:50PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

07:45PM EDT of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - BMRN PR Newswire

Oct 28, 2020

08:00AM EDT SHAREHOLDER ALERT: BioMarin Pharmaceutical, Inc. Sued for GlobeNewswire Inc

Oct 27, 2020

12:00PM EDT The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

11:00AM EDT Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingNovember 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioMarin Pharmaceuticals, Inc. (BioMarin or the Company) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020, inclusive (the Class Period). GlobeNewswire Inc

Oct 26, 2020

05:26PM EDT Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided. GlobeNewswire Inc

12:30PM EDT Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Oct 25, 2020

12:42PM EDT ROSEN, TRUSTED INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical GlobeNewswire Inc

Oct 23, 2020

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

12:00PM EDT Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class PR Newswire

Oct 22, 2020

08:31AM EDT BioMarin to Host Third Quarter 2020 Financial Results Conference Call and PR Newswire